Dr. Reddy's to Launch Generic Ozempic in India for Diabetes, Obesity Treatment

• Dr. Reddy's Laboratories received approval from India's drug regulator for a generic version of 'Semaglutide', known globally as 'Ozempic' and 'Wegovy'.
• The generic Ozempic is approved for diabetes treatment; approval for 'Wegovy' (obesity) is still pending.
• The company aims to sell 12 million injection pens in the first year post-launch, with Ozempic's patent expiring in March 2026.
• Dr. Reddy's Q3 net profit fell 14.4% to Rs 1,210 crore due to lower sales of 'Lenalidomide' in the US market.
• Despite profit decline, total revenue increased by 4.4% to Rs 8,727 crore, with strong 19% growth in the Indian market.

Why It Matters: Dr. Reddy's will bring an affordable generic 'Ozempic' to India, boosting diabetes and obesity treatment access.